When should clopidogrel and prasugrel be discontinued prior to surgery?

Preoperative Discontinuation of Clopidogrel and Prasugrel

For elective noncardiac surgery with high bleeding risk, discontinue clopidogrel 7-10 days before the procedure and prasugrel 7-10 days before surgery; for CABG specifically, stop clopidogrel at least 5 days before and prasugrel at least 7 days before surgery. 1, 2, 3, 4, 5

Type of Surgery Determines Timing

CABG Surgery

Clopidogrel:

• Ideal timing: ≥5 days before elective CABG 1, 2, 1, 4
• For urgent CABG with low ischemic risk: discontinue 5 days prior
• For urgent CABG with high ischemic/high bleeding risk: discontinue 3-5 days prior 1, 2
• Minimum for semi-urgent cases: 48-72 hours (though this increases bleeding risk) 4
• Recent Canadian data suggests 2-7 days may be acceptable based on heart team assessment of coronary anatomy, hemodynamic stability, and bleeding risk 6

Prasugrel:

• Ideal timing: ≥7 days before elective CABG 3, 4, 5
• Minimum for semi-urgent cases: 5 days 4
• The longer washout reflects prasugrel's more potent and prolonged antiplatelet effect 3

Noncardiac Surgery (High Bleeding Risk)

Both agents: discontinue 7-10 days before the procedure if it can be done safely 1, 2, 1, 2

The 2018 Canadian update provides more nuanced guidance for patients with coronary stents:

• Withhold clopidogrel and ticagrelor 5-7 days preoperatively
• Withhold prasugrel 7-10 days preoperatively 7

Low-to-Moderate Bleeding Risk Procedures

For minor dental, eye, or skin procedures, continue aspirin but discontinue clopidogrel 7-10 days before if safe to do so 1, 2, 1, 2

Critical Timing Considerations for Stent Patients

Elective Surgery Timing After Stent Placement

Defer elective surgery whenever possible:

• ≥6 weeks after bare metal stent (BMS) 1, 2, 1, 2
• ≥12 months after drug-eluting stent (DES) 1, 2, 1, 2
• The 2018 update suggests at least 3 months for elective surgery and at least 1 month for semi-urgent surgery after PCI with either stent type 7

Urgent Surgery in Stent Patients

If urgent surgery cannot be delayed:

• Within 6 weeks of BMS: continue both aspirin and clopidogrel perioperatively 1, 2, 1, 2
• Within 12 months of DES: continue both aspirin and clopidogrel perioperatively 1, 2, 1, 2

The risk of stent thrombosis with premature discontinuation carries up to 45% mortality in affected patients 1

Aspirin Management

Continue aspirin perioperatively in most cases, particularly:

• All CABG patients 1, 2, 1, 2, 4
• High cardiovascular risk patients undergoing noncardiac surgery 1, 2
• Patients with recent stents 7

Only discontinue aspirin for procedures with very high bleeding risk where it cannot be continued 1, 2

Pharmacologic Rationale

The different washout periods reflect distinct pharmacodynamics:

• Clopidogrel: Complete platelet function recovery by 5 days 8, 9
• Prasugrel: More delayed recovery, requiring 7 days for ≥75% of patients to return to baseline 8
• Recovery time depends on baseline platelet reactivity and degree of initial inhibition, not just the drug used 8

Common Pitfalls to Avoid

1. Don't use a "one-size-fits-all" approach: The FDA label explicitly warns to discontinue prasugrel "when possible" at least 7 days before surgery, acknowledging clinical judgment is required 5

2. Don't forget the stent timing: Stopping antiplatelet therapy too early after stent placement dramatically increases thrombotic risk—this trumps bleeding concerns in most urgent scenarios 1

3. Don't stop aspirin unnecessarily: In high-risk cardiovascular patients, continuing aspirin reduces mortality risk and can be done safely in most surgeries 1, 2, 4

4. Don't delay necessary surgery excessively: Recent evidence suggests shorter washout periods (2-3 days for clopidogrel, 2-4 days for ticagrelor) may be acceptable in urgent CABG when balanced against ischemic risk 6

Multidisciplinary Approach Required

Engage a heart team (cardiologist, surgeon, anesthesiologist) to weigh:

• Coronary anatomy and stent characteristics
• Hemodynamic stability
• Individual bleeding risk factors (age ≥75, weight <60 kg, bleeding history)
• Surgical urgency and bleeding risk of the specific procedure 3, 7, 6

For very high-risk patients requiring surgery within critical windows, consider bridging with short-acting IV antiplatelet agents (tirofiban, eptifibatide) stopped 4 hours before surgery 3